Wugen Inc is a clinical-stage biotechnology company based in St. Louis, MO, specializing in the development of off-the-shelf cellular therapies for cancer. With a focus on engineering the next generation of cell therapies, Wugen is dedicated to revolutionizing the treatment of difficult-to-treat blood cancers through their innovative NK and CAR-T platforms.
Through their pre-clinical and clinical pipeline, Wugen aims to provide effective and accessible treatments for a range of hematologic cancers, including T-ALL, LBL, AML, and solid tumors. With a team of experienced leaders and a commitment to scientific excellence, Wugen is at the forefront of advancing the field of cellular therapies in oncology.
Generated from the website